Respiratory Syncytial Virus (RSV) and Human Parainfluenza Virus 3 (HPIV-3) Infections Drug Development Pipeline Review, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

There are 127 products in development for RSV infections and key companies operating in this pipeline space include Johnson & Johnson, MedImmune and ReViral.

There are five products in development for HPIV-3 infections and companies operating in this pipeline space include Ansun Biopharma and Amarillo Biosciences.

Molecular targets present in the RSV and HPIV-3 pipeline landscapes include exo alpha sialidase and fatty acid synthase.

This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It comprehensively documents therapeutics under development for RSV and HPIV-3 infections, and features dormant and discontinued products.

Companies Mentioned

  • 3-V Biosciences Inc
  • Abivax SA
  • Ablynx NV
  • ADMA Biologics Inc
  • Amarillo Biosciences Inc
  • Anima Biotech Ltd
  • Ansun Biopharma Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Curevac AG
  • DBV Technologies SA
  • Enanta Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Gene Techno Science Co Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • iBio Inc
  • Immunwork Inc
  • Inovio Pharmaceuticals Inc
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • Kineta Inc
  • mAbxience SA
  • NanoBio Corp
  • Navigen Inc
  • Novavax Inc
  • Phoenix Biotechnology Inc
  • Profectus BioSciences Inc
  • Pulmocide Ltd
  • ReViral Ltd
  • Romark Laboratories LC
  • Takeda Pharmaceutical Co Ltd
  • Vault Pharma Inc
  • Virometix AG
  • Visterra Inc

Key Topics Covered

1 Table of Contents

2 Introduction

2.1 Report Coverage

2.2 Respiratory Syncytial Virus (RSV) Infections - Overview

2.3 Human Parainfluenza Virus 3 Infections - Overview

3 Therapeutics Development

3.1 Respiratory Syncytial Virus (RSV) Infections

3.2 Human Parainfluenza Virus 3 Infections

4 Therapeutics Assessment

4.1 Respiratory Syncytial Virus (RSV) Infections

4.2 Human Parainfluenza Virus 3 Infections

5 Companies Involved in Therapeutics Development

5.1 Respiratory Syncytial Virus (RSV) Infections

5.2 Human Parainfluenza Virus 3 Infections

6 Dormant Projects

6.1 Respiratory Syncytial Virus (RSV) Infections

6.2 Human Parainfluenza Virus 3 Infections

7 Discontinued Products

7.1 Respiratory Syncytial Virus (RSV) Infections

7.2 Human Parainfluenza Virus 3 Infections

8 Product Development Milestones

8.1 Respiratory Syncytial Virus (RSV) Infections

For more information about this report visit https://www.researchandmarkets.com/research/wcgkm6/respiratory?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Respiratory Drugs, Drug Discovery, Infectious Diseases Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Respiratory Drugs, Drug Discovery, Infectious Diseases Drugs